Galecto Inc (NASDAQ:GLTO) — Market Cap & Net Worth
Market Cap & Net Worth: Galecto Inc (GLTO)
Galecto Inc (NASDAQ:GLTO) has a market capitalization of $40.39 Million ($40.39 Million) as of May 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #22662 globally and #4750 in its home market, demonstrating a -0.20% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Galecto Inc's stock price $25.36 by its total outstanding shares 1592521 (1.59 Million). Analyse GLTO cash flow metrics to see how efficiently the company converts income to cash.
Galecto Inc Market Cap History: 2020 to 2026
Galecto Inc's market capitalization history from 2020 to 2026. Data shows change from $498.06 Million to $40.39 Million (-38.69% CAGR).
Index Memberships
Galecto Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.41 Trillion | 0.00% | #650 of 976 |
|
NASDAQ Composite
IXIC
|
$38.77 Trillion | 0.00% | #2171 of 3165 |
Weight: Galecto Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Galecto Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Galecto Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of GLTO by Market Capitalization
Companies near Galecto Inc in the global market cap rankings as of May 4, 2026.
Key companies related to Galecto Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Galecto Inc Historical Marketcap From 2020 to 2026
Between 2020 and today, Galecto Inc's market cap moved from $498.06 Million to $ 40.39 Million, with a yearly change of -38.69%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $40.39 Million | +10.21% |
| 2025 | $36.64 Million | +394.84% |
| 2024 | $7.41 Million | -74.17% |
| 2023 | $28.67 Million | -37.39% |
| 2022 | $45.78 Million | -62.05% |
| 2021 | $120.63 Million | -75.78% |
| 2020 | $498.06 Million | -- |
End of Day Market Cap According to Different Sources
On May 4th, 2026 the market cap of Galecto Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $40.39 Million USD |
| MoneyControl | $40.39 Million USD |
| MarketWatch | $40.39 Million USD |
| marketcap.company | $40.39 Million USD |
| Reuters | $40.39 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Galecto Inc
Galecto, Inc., a clinical-stage biotechnology company, develops molecule therapeutics for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company develops GB3226, a preclinical small molecule dual inhibitor of ENL-YEATS and FLT3 and GB1211, an oral small molecule inhibitor of galectin-3 to treat multiple types of oncology and liver disease indications. Galecto, In… Read more